- Suzhou Fuent Pharmaceutical Co., Ltd. completed its first round of financing of 125 million RMB, led by the former general manager of a securities company, with a post-investment valuation of 575 million RMB.
- The funds raised will be used for the construction of a 2,700-square-meter GMP facility in Phase I of the project. Upon completion, the facility will be dedicated to the R&D and production of innovative anti-tumor pharmaceuticals, which will be used for clinical trials in China and the United States.
